Two Diagnostics Businesses, the Same Operating Profit, a Quarter of the Revenue

A comparison the segment tables do not invite

Siemens Healthineers’ diagnostics segment turned over EUR 4,347 million in fiscal 2025 at an adjusted EBIT margin of 7.7%. That is about EUR 335 million of operating profit, or roughly USD 378 million at the average 2025 rate of EUR 1.00 = USD 1.13.

QIAGEN’s clinical business — USD 1,254 million carved out of a USD 2,090 million group — ran at an adjusted operating margin of 29.5%. That is about USD 370 million.

Two businesses, within USD 8 million of each other in operating profit, and one of them carries 3.92 times the revenue to get there. The margin ratio between them is 3.83. Neither company is badly run and neither number is a scandal. They are the same industry priced two different ways, and the difference is not the assay.

One disclosure caveat, stated before it is used against this argument: adjusted EBIT, adjusted operating margin and segment income are not identical measures, and Siemens and QIAGEN do not calculate them identically. The comparison survives the caveat because the gap is a multiple rather than a rounding, and because the two companies sit at the same point in the same value chain — reagents sold into clinical laboratories against a placed instrument.

The four margins in the reporting set

The arithmetic above multiplies disclosed revenue by disclosed margin, which is legitimate only where the company defines the denominator the same way; where a company publishes segment income directly — Thermo Fisher at USD 1,256 million — the product agrees to within rounding, which is a useful check on the other three.

Abbott, Roche, Danaher, BD and Hologic do not publish an operating margin at the diagnostics-line level. That absence is itself part of the story: the four franchises above are the ones whose disclosure lets a reader see the spread, and the spread is nearly four times from bottom to top.

Why breadth is a cost before it is a moat

The annuity model is not in dispute and no participant hides it. QuidelOrtho reports that 84% of its revenue is recurring rather than instrument sales. Siemens states the model in its own annual report: diagnostics generates profits mainly from long-term contracts that begin with an instrument placement and continue in reagent sales, producing a predictable and resilient revenue stream. Abbott’s Core Laboratory line, at USD 5,360 million, is four times its molecular line and six times its point-of-care line, and it is a reagent annuity attached to Alinity placements. The instrument is a toll booth and the reagents are the tolls.

But a toll booth with a wide menu charges less per vehicle. Once an analyser is placed, the manufacturer’s revenue depends on which tests the laboratory runs on it and what the buyer will pay for each. Clinical chemistry and routine haematology are commoditised, and they are precisely where a centralised tender sets the price: the Jiangxi biochemical alliance awarded 2,314 specifications at an average reduction of 70%. A narrow-menu specialist sells into the part of the menu where the price is set by clinical value, or by the scarcity of an equivalent assay, rather than by a specification comparison across four bidders.

Both visible margin moves in this reporting set are subtractions. Siemens moved from 5.3% to 7.7% — 2.4 points — through a cost programme. QIAGEN reached 29.5% with NeuMoDx and Dialunox discontinued. Neither company added assays to improve margin. In this industry margin is what remains after the menu has been pruned, and breadth is bought at the price of the tests a buyer can compare.

What our interviews say a laboratory is actually buying

Cost per reportable result. That was the phrase, or its direct equivalent, in almost every conversation in our primary layer for this market — depth interviews with laboratory directors and procurement staff, a procurement-side survey, and conference-floor discussions with the people who run the benches.

Directors described an evaluation that begins with labour, quality control, calibration, repeats, the service contract, downtime and the floor space of the instrument, and only then divides by reportable results. Reagent price per test is one input among seven. Under that metric breadth wins the placement, because one platform running more of the menu reduces the labour and quality-control burden attached to each result.

So the company with the deepest menu wins the instrument and then earns least on each test run on it. The purchasing decision and the pricing power sit at opposite ends of the same menu, and a company that optimises for the first has chosen its margin. That is the mechanism behind the four-row table above, and it is a better explanation of it than any claim about assay quality.

A second point came back as consistently. Buyers want fewer vendors. Consolidating onto a smaller number of platforms reduces validation files, service contracts, training and inventory — and a laboratory that is short of technologists values that reduction more than it values a per-test discount. That purchasing preference pushes this market towards concentration regardless of what happens to price, which is why the industry consolidates while its margins diverge.

Two ways to earn, and they do not converge

Own the placements and sell breadth at a thin margin: a volume business with a capital and service moat, whose real defence is the installed base and whose real vulnerability is that the base has to keep being refreshed. Danaher’s Cepheid installed base above 60,000 instruments, tripled since 2020, is that business stated as a number.

Or own the assays and sell depth at a high margin: a pricing business whose defence is regulatory and clinical, where a cleared assay with no equivalent sets its own price. QIAGEN’s 29.5% on a quarter of the revenue is that business stated as a number.

The market forecast of 5.74% a year to 2033 is silent on which of the two compounds better, because it is a revenue forecast for a perimeter rather than a returns forecast for a business model. What it does say is that the volume is not going away — and the margin table says who keeps the value of it.

The read-across for anyone allocating capital in this space is uncomfortable but simple. Revenue growth and margin expansion in in vitro diagnostics are, at the level of the menu, the same decision made in opposite directions. A company reporting both is usually reporting a mix shift inside its own portfolio; a company reporting one without the other has told you which side of the trade it chose. The full market report carries the four margins alongside the revenue lines they belong to, and the analysis of the clinical laboratory fee schedule follows the price side of the same question to its conclusion.

Companion analyses in this cluster: China’s Price Cut Is Worth Half a Point of the IVD Forecast, Not Four works through what the base year is and is not worth; The 43 Per Cent of the IVD Market That Files No Accounts covers the part of the market that publishes no margin line at all. Both sit under the Global In Vitro Diagnostics (IVD) Market report, 2026-2033, which carries the revenue lines these margins belong to, including the NGS library preparation and sequencing franchises where the same menu economics apply.

About the method

Roughly 70% secondary and 30% primary. Secondary work is the companies’ own filings and results releases for 2025, translated at disclosed average rates where revenue is reported in euros, Swiss francs or yen. Primary work — depth interviews with laboratory directors and procurement staff, a procurement-side survey, and conference-floor conversations — is used for mechanism only: what a buyer measures, why a platform is chosen, why a vendor count gets reduced. No figure in this article comes from a primary conversation; every one traces to a filing, and the arithmetic is shown so it can be checked.

The revenue lines, the segment build and the market perimeter sit in the Global In Vitro Diagnostics (IVD) Market report, 2026-2033. Two companion analyses follow from it: China’s Price Cut Is Worth Half a Point of the IVD Forecast, Not Four, on what the base year is and is not worth, and The 43 Per Cent of the IVD Market That Files No Accounts, on the part of the market with no margin line to read.